Tuhura Biosciences, Inc./Nv (HURA) Stock Price & Analysis

Tuhura Biosciences, Inc./Nv (HURA) fell 0.94% to USD 2.12 as of September 9, 2026 at 09:08 UTC, according to Nexqual real-time market data.

HURA last closed at USD 2.12; the session ranged USD 2.05–2.18 on volume of 314,888 shares. Market capitalization is —, with a 52-week range of USD 0.41–3.43 (NCM). Source: Nexqual, September 9, 2026 at 09:08 UTC.

Key Statistics (as of September 9, 2026 at 09:08 UTC)

Technical Analysis (HURA)

Nexqual's technical model rates HURA "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of September 9, 2026 at 09:08 UTC.

From Tuhura Biosciences, Inc./Nv's Latest SEC 10-K Filing (filed 2026-03-31)

Key Strengths & Strategy (as disclosed to the SEC)

• Our proprietary Immune FxTM technology platform, or IFx, is an innate immune agonist technology designed to "trick" the body's immune system to attack tumor cells by making tumor cells look like bacteria.
• We believe we are the first company developing immune modulating ADCs targeting the Delta Opioid Receptor on MDSCs.
• To our knowledge we are the only company developing ADCs targeting MDSCs where our ADCs are designed to be bi-specific/ bi-functional, i.e. , affecting two targets and having two functions: inhibiting tumor associated MDSC-related immune suppression and thereby making tumor susceptible to attack, while localizing checkpoint inhibitors where the tumor resides.
• IFx Innate Immune Agonist Development Program We have developed Immune Fx TM , or IFx, as an innate immune agonist technology designed to "trick" the body's immune system to attack tumor cells by making tumor cells look like bacteria and to thereby harness the natural power of innate immunity by leveraging natural mechanisms conserved throughout evolution to recognize threats from foreign pathogens like bacteria or viruses.

Partnerships

• He also led CTI Biopharma in the negotiation of the development and commercial license agreement with Baxalta.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 09:08 UTC. This page is informational and not investment advice.